Crewe Advisors’s Compass Therapeutics CMPX Stock Holding History

Crewe Advisors’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.6K	Buy	+11,696	New	+$34.5K	﹤0.01%	553

Other funds holding CMPX

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

Wealth Enhancement Advisory Services

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Wealthcare Advisory Partners West Chester, Pennsylvania $5.27B AUM 22.23% 1-Year Est. Return

Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Independent Financial Group San Diego, California $5.35B AUM 43.78% 1-Year Est. Return

ACT Advisors Asheville, North Carolina $301M AUM 23.36% 1-Year Est. Return

Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return

Wealthcare Capital Partners West Chester, Pennsylvania $242M AUM 18.96% 1-Year Est. Return

Crewe Advisors's CMPX Position: Q2 2026 in Review

Crewe Advisors opened a new position in Compass Therapeutics (CMPX) in Q2 2026: 11,696 shares worth $25.6K. The stake represents ﹤0.01% of the portfolio and ranks #553 among its holdings.

21 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

Crewe Advisors held 11,696 shares of Compass Therapeutics worth $25.6K as of Q2 2026.
Compass Therapeutics was a new Crewe Advisors position in Q2 2026.
Compass Therapeutics made up ﹤0.01% of Crewe Advisors's portfolio in Q2 2026, its #553 holding.
21 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Crewe Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.